<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091219</url>
  </required_header>
  <id_info>
    <org_study_id>UL1TR000124-1954</org_study_id>
    <secondary_id>1P50AR063020-01</secondary_id>
    <secondary_id>UL1TR000124</secondary_id>
    <nct_id>NCT02091219</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function</brief_title>
  <official_title>The Effects of Vitamin D3 Versus 25OHD3 (HyD) on Serum Vitamin D Metabolites and Markers of Mineral Metabolism and Immune Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of two different forms of vitamin D&#xD;
      supplements (vitamin D3 and 25-hyrdroxyvitamin D3 [25(OH)D3]) on vitamin D levels in the&#xD;
      blood, and on markers of skeletal and immune health. This study is designed as a pilot study.&#xD;
      A multi-ethnic cohort of 48 patients will be included (12 Caucasian, 12 African American, 12&#xD;
      Hispanic/Latino, 12 Asian/Asian American). Potential study candidates will undergo a&#xD;
      screening visit during which a medical history will be taken, a physical exam performed, a&#xD;
      dietary questionnaire administered, and blood collected. The purpose of the screening visit&#xD;
      is to identify vitamin D-deficient (25-hydroxyvitamin D &lt;20 ng/ml) individuals who are&#xD;
      candidates for vitamin D supplementation. Eligible patients will then be randomly assigned to&#xD;
      receive either vitamin D3 (2400 IU/day) or 25(OH)D3 (20 mcg/day) for 16 weeks. After&#xD;
      initiating supplementation, study patients will return for follow-up visits at weeks 4, 8,&#xD;
      and 16. At each visit, blood will be collected to assess vitamin D levels in the blood, as&#xD;
      well as markers of skeletal and immune function. Participation in this study will therefore&#xD;
      involve a total of 5 visits (1 screening visit, 1 randomization visit during which&#xD;
      participants will receive their study supplements, 3 follow-up visits). After all data is&#xD;
      collected, changes in vitamin D levels in the blood following supplementation with either&#xD;
      vitamin D3 versus 25(OH)D3 will be determined, and correlated to markers of calcium balance&#xD;
      and immune function. Knowledge gained from this study may have a significant impact on how&#xD;
      vitamin D status is defined, and how vitamin D repletion is administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 7, 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total serum 25D</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum free 25D</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum total 1,25D</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total free 1,25D</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum calcium</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary calcium</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum iPTH</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum bone turnover markers</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of immune function</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>25(OH)D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 micrograms/day by mouth for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,400 IU/day by mouth for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>2400 IU/day by mouth for 16 weeks</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25(OH)D3</intervention_name>
    <description>20 micrograms/day by mouth for 16 weeks</description>
    <arm_group_label>25(OH)D3</arm_group_label>
    <other_name>Calcifediol</other_name>
    <other_name>HyD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  25D &lt; 20 mg/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  25D &gt; 20 ng/ml at time of screening&#xD;
&#xD;
          -  Clear signs of infection at time of screening (coughing, sneezing, wheezing,&#xD;
             frequency, dysuria)&#xD;
&#xD;
          -  History of conditions that would influence intestinal absorption of vitamin D3 or&#xD;
             25OHD3 supplements&#xD;
&#xD;
          -  History of nephrolithiasis, primary hyperparathyroidism, or other metabolic bone&#xD;
             disease&#xD;
&#xD;
          -  History of chronic kidney disease (defined as CrCl &lt; 30 ml/min)&#xD;
&#xD;
          -  History of rheumatologic or autoimmune conditions&#xD;
&#xD;
          -  History of sarcoidosis&#xD;
&#xD;
          -  History of active or latent tuberculosis&#xD;
&#xD;
          -  History of HIV&#xD;
&#xD;
          -  History of hyperthyroidism&#xD;
&#xD;
          -  History of chronic glucocorticoid use defined as the equivalent of 5 mg of prednisone&#xD;
             per day for more than 2 months within the last 6 months&#xD;
&#xD;
          -  History of use of medications known to affect calcium/vitamin D metabolism, bone&#xD;
             metabolism, and immune response&#xD;
&#xD;
          -  Hypercalcemia&#xD;
&#xD;
          -  Hypercalcinuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John S Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles Department of Orhtopaedic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Clinical and Translational Research Center (CTRC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>John Adams, M.D.</investigator_full_name>
    <investigator_title>Professor, Department of Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <keyword>Hypovitaminosis D</keyword>
  <keyword>Free 25-hydroxyvitamin D</keyword>
  <keyword>Total 25-hydroxyvitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

